Analysts expect over 2020 rising revenue Genmab

Over the current book year the total revenu from the company based in Kopenhagen will be 9.85 billion Danish Krone (consensus estimates). This is rather significant more than 2019's revenue of 5.37 billion Danish Krone.

Historical revenues and results Genmab plus estimates 2020

The analysts expect for 2020 a net profit of 4.75 billion Danish Krone. The majority of the analysts expects for this year a profit per share of 72.38 Danish Krone. With this the price/earnings-ratio is 32.58.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the pharmaceutical companies equals a moderate 0.38 percent.

Based on the current number of outstanding shares Genmab 's market capitalization is 144.59 billion Danish Krone. The Genmab stock was the past 12 months quite unstable. Since last February the stock is even 44 percent higher. This year the stock price moved between 1083 and 2786 DKK.

Historical stock prices Genmab

Click here for dividend Genmab.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.